Vaxcyte says Phase 3 OPUS-1 trial of VAX-31 meets primary endpoints in adults versus Prevnar 20, Capvaxive
Bitget2026/10/05 10:05Vaxcyte reported positive topline results from OPUS-1, a pivotal adult Phase 3 trial of its VAX-31 pneumococcal vaccine. The study met its primary goals across age groups, supporting the program’s case for regulatory filing in the US. Results indicated immune responses broadly comparable to leading adult pneumococcal vaccines, with added coverage for strains not included in them. Safety and tolerability were broadly similar to existing comparator vaccines in the trial. Additional Phase 3 readouts are expected in the first half of 2027, ahead of a planned BLA submission in the first half of 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050600PRIMZONEFULLFEED9839330) on October 05, 2026, and is solely responsible for the information contained therein.
- Vaxcyte reported positive topline results from OPUS-1, a pivotal adult Phase 3 trial of its VAX-31 pneumococcal vaccine.
- The study met its primary goals across age groups, supporting the program’s case for regulatory filing in the US.
- Results indicated immune responses broadly comparable to leading adult pneumococcal vaccines, with added coverage for strains not included in them.
- Safety and tolerability were broadly similar to existing comparator vaccines in the trial.
- Additional Phase 3 readouts are expected in the first half of 2027, ahead of a planned BLA submission in the first half of 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
